Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 1;79(1):e11-e17.
doi: 10.1097/FJC.0000000000001155.

Considerations for Inotrope and Vasopressor Use in Critically Ill Patients With Pulmonary Arterial Hypertension

Sarah K Adie  1 , Ahmad A Abdul-Aziz  2 , Scott W Ketcham  3 , Victor M Moles  3
Affiliations
Review

Considerations for Inotrope and Vasopressor Use in Critically Ill Patients With Pulmonary Arterial Hypertension

Sarah K Adie et al. J Cardiovasc Pharmacol. .

Abstract

Pulmonary arterial hypertension (PAH) is a rare and progressive cardiopulmonary disease, characterized by pulmonary vasculopathy. The disease can lead to increase pulmonary arterial pressures and eventual right ventricle failure due to elevated afterload. The prevalence of PAH in patients admitted to the intensive care unit (ICU) is unknown, and pulmonary hypertension (PH) in the ICU is more commonly the result of left heart disease or hypoxic lung injury (PH due to left heart disease and PH due to lung diseases and/or hypoxia, respectively), as opposed to PAH. Management of patients with PAH in the ICU is complex as it requires a careful balance to maintain perfusion while optimizing right-sided heart function. A comprehensive understanding of the underlying physiology and underlying hemodynamics is crucial for the management of this population. In this review, we summarized the evidence for use of vasopressors and inotropes in the management of PH and extrapolated the data to patients with PAH. We strongly believe that the understanding of the hemodynamic consequences of inotropes and vasopressors, especially from data in the PH population, can lead to better management of this complex patient population.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

References

    1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.
    1. Torbic H. Management of pulmonary arterial hypertension in the ICU. J Pharm Pract. 2019;32:303–313.
    1. Broder N, Zolty R. Pulmonary arterial hypertension in the ICU. In: Oropello JM, Pastores SM, Kvetan V, eds Critical Care. New York: McGraw-Hill Education; 1AD. Available at: http://accessmedicine.mhmedical.com/content.aspx?aid=1136414325 . Accessed May 3, 2021.
    1. Jentzer JC, Mathier MA. Pulmonary hypertension in the intensive care unit. J Intensive Care Med. 2016;31:369–385.
    1. Olsson KM, Halank M, Egenlauf B, et al. Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:46–52.

MeSH terms